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Abstract
Background:	Gastrointestinal	amyloidosis	causes	dysmotility.	A	comprehensive	his-
tological	analysis	to	explain	these	symptoms	is	lacking.	Therefore,	we	systematically	
examined	histological	features	of	 intestinal	dysmotility	in	patients	with	AL	and	AA	
amyloidosis,	compared	to	controls.
Methods:	Autopsy	tissue	material	from	small	bowel	and	colon	was	used	for	histo-
logical	(semiquantitative)	evaluation	of	the	mucosa,	blood	vessels,	muscular	layers,	
enteric	nervous	system	(ENS)	and	the	 interstitial	cells	of	Cajal	 (ICC),	using	hema-
toxylin	and	eosin,	periodic	acid	Schiff,	Elastic	von	Gieson	and	Congo	red	staining,	
and immunohistochemistry with α-smooth	muscle	actin,	HuC/D,	S100	and	CD117	
antibodies,	 according	 to	 guidelines	 of	 the	 Gastro	 2009	 International	 Working	
Group.
Key Results:	Amyloid	deposits	were	present	in	the	vascular	walls	of	all	amyloidosis	
patients.	In	the	mucosa,	amyloid	was	found	in	67%	of	AA	patients.	The	muscular	lay-
ers	were	 involved	 in	64%	of	amyloidosis	patients,	most	prominent	 in	AA	patients,	
associated	with	the	presence	of	polyglucosan	inclusion	bodies,	but	not	with	either	
abnormal α-actin	patterns	or	fibrosis.	Amyloid	in	the	muscularis	propria	surrounding	
the	myenteric	plexus	was	found,	but	not	inside	the	myenteric	plexus.	These	deposits	
might	be	related	to	loss	of	the	ICC	network,	but	there	was	no	association	with	de-
creased neuronal or nerve fiber density.
Conclusions & Inferences: We hypothesize that intestinal dysmotility in amyloidosis 
patients	 is	 a	 sequential	 process:	 amyloid	 deposition	 starts	 in	 the	 vasculature,	 fol-
lowed	 by	 involvement	 of	 the	muscular	 layers,	 ICC	 loss,	 and	 potentially	 affect	 the	
myenteric	plexus.	This	final	stage	may	be	accompanied	by	clinical	symptoms	of	se-
vere intestinal dysmotility.
K E Y W O R D S
amyloid,	amyloidosis,	gastrointestinal	tract,	histology,	intestinal	dysmotility
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1  | INTRODUC TION
Amyloidosis	is	a	diverse	group	of	disorders	characterized	by	extra-
cellular	abnormal	fibrillar	protein	deposits	in	various	tissues,	includ-
ing	the	gastrointestinal	(GI)	tract,	resulting	in	tissue	damage	caused	
by several mechanisms.1,2
Amyloid	deposits	can	be	found	in	all	layers	and	structures	of	the	
bowel	 wall,	 including	 musculature,	 vasculature,	 and	 neural	 struc-
tures.	In	the	muscles,	this	leads	to	pressure	atrophy,	while	in	vessel	
walls amyloid deposits result in ischemia and infarction.3 Different 
types of amyloidosis show different damage patterns.4	AL	amyloi-
dosis,	 that	 is,	 light	chain	amyloid	associated	with	B	cell	dyscrasias,	
supposedly shows a preference for the muscularis mucosae and 
muscularis	propria,	resulting	in	myopathy,5‒7 which causes constipa-
tion,	mechanical	obstruction	or	chronic	 intestinal	pseudo-obstruc-
tion.6‒8	In	AA	amyloidosis,	associated	with	inflammatory	disorders,	
fine granular amyloid deposits are mainly found in the lamina pro-
pria	(mucosa),	resulting	into	diarrhea	and	malabsorption,	and	in	the	
myenteric	plexus,	leading	to	neuropathy.5,6,8	Hence,	both	myopathy	
and neuropathy may be the underlying cause of intestinal dysmotil-
ity.	Amyloidosis	of	the	GI	tract	can	therefore	be	classified	as	a	sec-
ondary intestinal motility disorder.9 Intestinal dysmotility is present 
in	10-70%	of	patients	with	AL	and	AA	amyloidosis10;	however,	the	
literature	 is	mainly	 restricted	 to	case	 reports,	 rarely	 larger	patient	
series are described.
Guidelines	 for	 studying	 the	 intestinal	 neuromusculature	 have	
been	presented	by	the	Gastro	2009	International	Working	Group.9 
The present study is the first study using these guidelines for histo-
logical evaluation of tissues from amyloidosis patients. The aim was 
to	perform	a	systematic	explorative	study	of	the	histological	charac-
teristics	of	intestinal	dysmotility	in	amyloidosis	patients,	in	order	to	
develop insights in the mechanisms.
2  | METHODS
2.1 | Subjects
Archived	autopsy	formalin-fixed	paraffin-embedded	tissue	samples	
of segments of small bowel (n = 10) and colon (n = 12) were obtained 
from amyloidosis patients selected for the presence of amyloid de-
posits in the intestinal wall. Complete autopsy records were avail-
able in all patients; and patient dossiers were available in 11 of 14 
patients.	Amyloidosis	patients	were	included	in	the	AL	or	AA	group,	
based on the diagnosis described in the autopsy reports and patients 
dossiers.	Amyloid	A	antibody	(Table	1)	was	used	to	confirm	the	diag-
nosis	AA	or	non-AA	amyloidosis.	Control	autopsy	material	of	ileum	
(n = 22) and colon (n = 23) was obtained from patients without in-
testinal motility problems (according to the pathology reports) and 
considered as normal.
The study was approved by the local ethics committee (reference 
number	2014-1256).	Samples	were	obtained	in	accordance	with	the	
Code	of	Conduct	of	the	Federation	of	Medical	Scientific	Societies	in	
The	Netherlands.11
2.2 | Tissue preparation
Sections	were	cut	from	formalin-fixed	paraffin-embedded	full-thick-
ness	tissue	blocks	for	conventional	histology	or	immunohistochem-
istry.	Sections	were	deparaffinized,	rehydrated	in	xylene	and	ethanol	
series,	and	rinsed	in	tap	water	by	standard	protocol.
2.3 | Histological staining
Sections of 4 μm	were	used	for	hematoxylin	and	eosin	(H&E)	and	pe-
riodic	acid	Schiff	(PAS)	staining.	Elastic	von	Gieson	(EVG)	and	Congo	
red	staining	were	performed	on	6-μm sections. Tissues were stained 
by	standard	protocols	in	a	Medite	TST	30	stainer	(Klinipath,	Duiven,	
The	Netherlands).
2.4 | Immunohistochemistry
Immunohistochemical	 staining	 was	 performed	 on	 4-μm sections. 
Antibodies,	suppliers,	and	dilutions	are	listed	in	Table	1.
Key Points
• We performed a comprehensive and systematic histo-
logical	analysis	to	explain	intestinal	symptoms	of	dysmo-
tility	 in	 amyloidosis	 patients,	 since	 this	 is	 currently	
lacking.
•	 Amyloid	 deposits	were	 found	 in	 blood	 vessels	 (all	 pa-
tients	with	AL	and	AA),	the	mucosa	(AA),	and	in	the	mus-
cular	 layers	 (AL	and	AA)	around	 the	myenteric	plexus,	
probably related to loss of interstitial cells of Cajal.
• We hypothesize that intestinal dysmotility in amyloido-
sis patients is a sequential process.
TA B L E  1   Primary antibodies used for immunohistochemistry
Antibody Clone Manufacturer Dilution Antigen retrieval
Amyloid	A Reu-86.2 Monosan,	Sanbio 1:80 None
HuC/D 16A11 Molecular	Probes 1:600 Sodium	citrate	10	mmol/L	(pH	6.0)	30	min	at	100°C
S100 POLYCLONAL DAKO 1:10 000 EDTA	pH	9	10	min	at	96°C
CD117 YR145 Immunologic 1:200 None
α-smooth	muscle	actin	(α-SMA) 1A4 Sigma 1:7500 None
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For	 HuC/D	 staining,	 antigen	 retrieval	 was	 performed	 in	 so-
dium	citrate	(pH	6)	at	100°C	for	30	minutes.	Subsequently,	endoge-
nous	peroxidase	was	blocked	with	3%	hydrogen	peroxide	in	PBS	for	
20	minutes.	Sections	were	then	rinsed	in	PBS	and	incubated	with	pri-
mary	 antibody	anti-HuC/D	at	4°C	overnight.	After	washing	 in	PBS,	
sections were incubated for 30 minutes with a secondary antibody 
(Powervision	 poly-HRP	 anti-Ms/Rb/Rt	 IgG,	 Immunologic,	 Duiven,	
The	Netherlands)	at	room	temperature.	Subsequently,	sections	were	
rinsed	in	PBS	and	immunoreactivity	was	developed	with	PowerDAB	
(Immunologic)	 for	 7	minutes	 at	 room	 temperature.	 Finally,	 sections	
were	rinsed	in	tap	water,	counterstained	with	hematoxylin,	rinsed	in	
tap	water,	dehydrated	in	100%	ethanol	and	xylene,	and	mounted	with	
Permount.
The other immunohistochemical staining reactions were per-
formed	 in	 an	 automated	 LabVision	 Autostainer	 480	 (Klinipath,	
Duiven,	 The	 Netherlands).	 The	method	 used	 for	 antigen	 retrieval	
depended	 on	 the	 antibody	 (Table	1).	 Endogenous	 peroxidase	 was	
blocked	 with	 3%	 hydrogen	 peroxide	 in	 methanol	 for	 10	minutes.	
Sections were incubated with primary antibody for 60 minutes. 
Subsequently,	 the	 sections	 were	 incubated	 with	 Powervision	
poly-HRP	anti-Ms/Rb/Rt	for	30	minutes,	followed	by	staining	with	
PowerDAB	for	7	minutes	and	counterstaining	with	hematoxylin	for	
1	minute.	All	incubations	were	performed	at	room	temperature.
Tissue	blocks	containing	different	tissue	types	were	used	as	con-
trols	 for	 the	 immunohistochemical	 staining	 reactions,	with	 known	
staining patterns for both positive and negative stained tissues.
2.5 | Microscopic analysis
Sections were evaluated blind to diagnosis by two observers. The 
histology	of	the	bowel	wall	was	examined	by	H&E.	PAS	was	used	to	
verify the presence or absence of polyglucosan inclusion bodies in 
the muscularis propria. The presence or absence of fibrosis was as-
sessed	in	the	submucosa,	muscularis	propria,	and	myenteric	plexus	
on	EVG-stained	sections.	Congo	red	stained	sections	were	used	to	
evaluate	 the	presence	of	 amyloid	deposits	 in	 the	mucosa,	 submu-
cosa,	muscularis	propria,	and	vascular	walls.
Immunohistochemically stained sections were assessed by 
semiquantitative scoring using visual analysis to evaluate system-
atically	 the	smooth	muscle	 layers	and	neuronal	 structures,	as	pre-
viously described.12 α-Smooth	 muscle	 actin	 (α-SMA)	 staining	 was	
used to assess the muscular layers. Staining intensities of circular 
and longitudinal muscle layers were classified in two grades: 0 (no/
weak)	and	1	 (strong	staining	 intensity).12 The presence of neurons 
in	ganglia	was	analyzed	on	HuC/D-stained	sections.	The	number	of	
neurons	 in	relation	to	the	present	plexus	was	estimated	 in	HuC/D	
sections	as	follows:	0	(no	neurons),	1	(low	neuronal	density),	and	2	
(high neuronal density). S100 was used to assess the distribution 
of	nerve	fibers	(including	nuclei	of	glial	cells)	in	the	submucosa,	the	
myenteric	plexus,	and	both	muscle	layers	of	the	muscularis	propria.	
The degree of distribution was scored as follows: 0 (no/low density) 
and 1 (high density of positive fibers).12	The	network	of	interstitial	
cells	of	Cajal	(ICCs)	surrounding	the	myenteric	plexus	was	estimated	
on	 CD117-stained	 sections	 as	 described	 earlier.13 The percentage 
of	the	circumference	which	is	covered	by	CD117-positive	cells	was	
rated	from	0%	to	100%	in	10%	increments.	Thus,	a	percentage	of	0%	
represented no positive cells around the ganglia and in sections es-
timated	as	100%	the	ganglia	were	completely	surrounded	by	CD117-
positive cells.
2.6 | Statistical analysis
Categorical variables were described by percentages. Differences 
between	categorical	variables	were	assessed	by	the	chi-squared	test	
(likelihood	 ratio,	exact	P-values	compared	with	 the	control	group).	
Continuous variables were presented as means ± standard deviation 
(SD).	The	Mann-Whitney	test	was	performed	to	compare	the	CD117	
scores	 between	 groups.	A	P-value	 of	 0.05	was	 considered	 signifi-
cant.	Data	were	analyzed	by	 the	 IBM	SPSS	Statistics	22	Software	
(SPSS	 Inc.,	 Chicago,	 IL,	 USA),	 GraphPad	 Prism	 version	 5.00	 for	
Windows	 (GraphPad	Software,	 San	Diego,	CA,	USA),	 and	RStudio	
version	1.1.419	(RStudio,	Inc.,	Boston,	MA,	USA).
3  | RESULTS
3.1 | Patients
Tissue	 material	 of	 8	 AL	 amyloidosis	 patients	 (mean	 age	
66	±	13	years,	 88%	male),	 6	 AA	 amyloidosis	 patients	 (mean	 age	
57	±	20	years,	 100%	 male)	 and	 26	 control	 patients	 (mean	 age	
65	±	14	years,	58%	male)	was	evaluated	in	this	study.	The	AL	amy-
loidosis	group	(n	=	8)	consisted	of	5	small	bowel	and	7	colon	cases,	
from	4	patients	tissues	of	both	 locations	were	analyzed.	The	AA	
amyloidosis group (n = 6) included 5 small bowel and 5 colon tis-
sues,	 from	4	patients	tissues	of	both	 locations	were	assessed.	 In	
the	control	group	(n	=	26),	22	small	bowel	and	23	colon	cases	were	
included.
Among	 the	 patients	 with	 amyloidosis,	 gastrointestinal	 bleeding	
was	reported	in	two	AL	patients	and	in	two	AA	patients.	Ileus	was	re-
ported	in	one	AL	and	three	AA	cases,	of	which	one	patient	with	severe	
dysmotility of the esophagus. Clinical symptoms of gastrointestinal 
involvement	of	the	other	patients	were	absent	or	unknown	(Table	2).
3.2 | Amyloid deposition
The	 presence	 of	 amyloid	 deposits	 in	 the	mucosa,	 muscularis	 mu-
cosae,	muscularis	propria,	myenteric	plexus	and	vascular	walls	was	
assessed	by	Congo	red	staining	(Figure	1).	Overall,	amyloid	deposits	
were more frequently found in both the mucosa and muscularis mu-
cosae	of	AA	amyloidosis	 compared	 to	AL	 amyloidosis,	 no	 amyloid	
was present in the control group. There was no difference between 
small	 bowel	 and	 colon	 tissues	 of	 the	 same	 patients.	 Amyloid	 de-
posits	were	present	in	all	layers	of	the	intestinal	wall,	except	inside	
the	myenteric	 plexus.	 All	 cases	 with	 amyloidosis	 showed	 amyloid	
deposits	 in	 the	 vascular	walls,	most	 prominent	 in	 the	 submucosa.	
In	three	patients,	extravasation	of	erythrocytes	was	present	in	the	
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submucosa	(one	colon	AL,	two	small	bowel	AA),	but	there	were	no	
signs	of	chronic	blood	loss	(hemosiderin	deposits).	Mucosal	presence	
of	amyloid	was	most	pronounced	in	the	colon	of	AA	patients	(80%	
vs	0%	in	AL	patients,	P	=	0.015).	A	comparable	trend	was	found	in	
the	small	bowel	(60%	vs	0%,	P	=	0.167).	No	other	differences	were	
shown	between	the	AL	and	AA	groups	(Figure	1).
3.3 | Bowel musculature
The presence of amyloid in the musculature of the bowel wall did 
not result in aberrant staining patterns of α-SMA	in	small	bowel	or	
colon	(Figure	2),	which	would	suggest	that	no	significant	α-actin	fil-
ament abnormalities were present in these patients. Polyglucosan 
inclusion	bodies,	as	a	sign	of	myopathy,	were	present	in	the	small	
bowel	 (n	=	3)	 and	 colon	 (n	=	1)	 of	 patients	with	 amyloidosis,	 but	
there was no consistent relation with the presence of muscular 
amyloid depositions (Figure 2). Some control patients also pre-
sented with polyglucosan bodies in small bowel (n = 3) and colon 
(n = 1). There was no relation between the presence of fibrosis and 
amyloid (Figure 2).
3.4 | Enteric nervous system
No	 amyloid	 deposits	 were	 found	 inside	 the	 myenteric	 plexus,	 in	
some	 cases,	 amyloid	 deposits	were	present	 in	 the	 smooth	muscle	
tissue	around	this	plexus	 (Figure	1).	The	presence	of	neurons	rela-
tive	to	nerve	fibers	was	evaluated	by	HuC/D	staining,	and	the	nerve	
fiber density was assessed by S100 staining. In both the small bowel 
F I G U R E  1  Amyloid	deposition	in	the	bowel	wall.	A,	Localization	of	amyloid	deposits	in	various	layers	of	the	intestinal	wall.	AL	compared	
to	AA	amyloidosis,	in	small	bowel	and	colon	tissues.	B	and	C,	Amyloid	in	the	smooth	muscle	layers	surrounding	the	myenteric	ganglion	in	
an	AA	patient,	double	staining	S100	(brown)	and	Congo	red	(clear	red	in	B	and	apple	green	in	(C).	Mu	mucosa,	MM	muscularis	mucosae,	CL 
circular	layer,	LL	longitudinal	layer,	MP	myenteric	plexus,	BV blood vessel walls. *P < 0.05 vs control
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F I G U R E  2   Circular plot of aberrations 
in the musculature of the bowel wall in 
association with amyloidosis in small 
bowel (left side) and colon (right side). 
Amyloidosis	patients	were	divided	
according to the presence of amyloid 
deposits	in	the	musculature	(A+:	present,	
A−:	absent).	Percentage	of	cases	are	
given.	C,	control;	PAS, periodic acid Schiff 
staining; SMA, smooth muscle actin
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and	colon,	no	differences	were	found	between	the	control,	AL	and	
AA	groups	in	the	submucosal	and	myenteric	plexus	as	well	as	in	the	
muscularis	propria	(Figure	3A).
3.5 | Myenteric ICC network
Lower	percentages	of	the	CD117	positive	ICC	network	surrounding	the	
myenteric	plexus	were	found	in	the	amyloidosis	groups	compared	to	
the	control	group,	both	in	the	small	bowel	and	colon	(Figure	3B,C).	In	
the	colon,	the	density	of	the	ICC	network	was	significantly	lower	in	the	
AL	group	compared	to	controls	(P = 0.019). Patients with amyloid de-
posits	in	the	muscularis	propria	seemed	to	have	a	reduced	ICC	network	
(red	points	in	Figure	3B).	In	the	small	bowel	of	the	AL	group,	no	amyloid	
in	 the	muscularis	propria	was	present,	while	 in	 two	cases	of	 the	AA	
group amyloid was found in the muscularis propria of the small bowel 
(percentage	ICCs	around	the	myenteric	plexus	0%	and	30%,	red	points	
in	Figure	3B).	In	the	colon,	amyloid	deposits	in	the	muscularis	propria	
were	found	in	three	AL	patients	(percentage	ICCs	0%),	and	in	one	AA	
patient	(percentage	ICCs	10%).
4  | DISCUSSION
The objective of this study was to investigate the mechanisms that 
cause	 intestinal	 dysmotility	 in	 amyloidosis	 patients,	 by	 analyzing	
histological	 features	 in	 a	 systematic	way.	Histological	 findings	 for	
individual	amyloidosis	patients	are	summarized	in	Table	2.	Amyloid	
deposits were present in the vascular walls of all amyloidosis pa-
tients,	 regardless	of	 type,	most	prominent	 in	 the	 submucosa.	This	
may contribute to intestinal dysmotility by causing ischemia and in-
creased permeability.14	 Gastrointestinal	 bleeding	might	 be	 caused	
by disruption of blood vessel walls as a result of amyloid deposi-
tion,15,16 which was reported in four of our patients.
Endoscopic	 examination	 of	 amyloidosis	 patients	 frequently	
shows	a	granular	and	friable	appearance	of	the	mucosa,8,17,18 which 
can	be	correlated	with	amyloid	deposits,	as	was	present	in	our	study	
in	67%	of	AA	patients.	 Involvement	of	 the	mucosa	can	 lead	 to	di-
arrhea and malabsorption.15,17 It should thus be noted that endo-
scopic	biopsies	taken	to	determine	the	presence	of	amyloid,	should	
also	include	submucosal	tissue.	When	only	the	mucosa	is	examined,	
F I G U R E  3  Histological	findings	in	the	enteric	nervous	system	and	the	ICC	network.	A,	The	density	of	neurons	and	nerve	fibers	was	
estimated	by	HuC/D	and	S100	immunohistochemical	staining,	respectively.	Results	for	small	bowel	and	colon	showed	no	differences	
between	the	AL,	AA	and	control	groups.	B,	Percentage	of	CD117	positive	cells	(ICCs)	around	the	myenteric	plexus.	The	black	points	
represent	cases	without	amyloid	in	the	muscularis	propria,	the	red	points	cases	with	amyloid	in	muscularis	propria.	Horizontal	lines	show	the	
medians.	C,	Picture	of	the	positive	stained	ICC	network	around	the	myenteric	plexus	shows	control	tissue	of	small	bowel.	The	percentage	
in	this	picture	was	scored	as	100%.AL, AL	amyloidosis,	AA, AA	amyloidosis,	C,	control	group,	CL,	circular	layer	of	muscularis	propria,	LL, 
longitudinal	layer	of	muscularis	propria,	ICC,	interstitial	cells	of	Cajal.	*P < 0.05 vs control
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particularly	in	AL	cases,	the	results	are	unreliable.	Muscular	involve-
ment	 was	 present	 in	 64%	 of	 amyloidosis	 patients,	 with	 deposits	
in	all	muscular	 layers,	 again	most	pronounced	 in	AA	patients.	The	
presence of amyloid deposits in the muscularis propria tended to 
be	associated	with	 the	presence	of	polyglucosan	 inclusion	bodies,	
which may be related to symptoms of intestinal dysmotility and con-
stipation,19 although this could not be confirmed in our study. The 
presence of amyloid deposits was not related to either abnormal α-
actin	patterns	or	fibrosis,	suggesting	that	amyloid-induced	muscular	
failure	 is	not	because	of	primary	myopathy,	but	more	 likely	due	to	
mechanical failure.
Histological	 signs	 of	 direct	 neuropathy	 could	 not	 be	 found	 in	
this	study.	No	amyloid	was	found	inside	the	myenteric	plexus.	The	
presence	of	amyloid	in	the	smooth	muscle	surrounding	the	plexus,	
which has been suggested to cause secondary degeneration or loss 
of	neurons,5 was not associated with decreased neuronal or nerve 
fiber	 density	 in	 our	 study.	 Based	 on	 our	 observations,	 we	 reject	
the	hypothesis	that	that	intestinal	pseudo-obstruction	is	caused	by	
myopathy	in	AL	amyloidosis	and	neuropathy	in	AA	amyloidosis.5,20 
This	 hypothesis	 is	 based	on	 the	 study	of	 Tada	 et	al,	where	 all	 pa-
tients were on total parenteral nutrition because of severe intestinal 
pseudo-obstruction.5	These	patients	are	very	 likely	 in	a	 late	stage	
of	 amyloidosis	 induced	motility	 disorder,	where	 distinction	 of	 dif-
ferent	mechanisms	might	be	hard.	In	our	study,	only	one	AA	patient	
received	total	parenteral	nutrition,	which	was	given	because	of	dys-
motility of the esophagus. This patient showed amyloid deposits in 
the	mucosa	and	muscle	layers	of	the	intestines.	Although	no	amyloid	
was	found	in	the	myenteric	plexus,	the	ICC	network	and	nerve	fiber	
network	were	reduced.
We propose an alternative hypothesis about intestinal dys-
motility	 in	 patients	 with	 amyloidosis	 (Figure	4).	 Firstly,	 amyloid	
deposition	occurs	 in	the	vascular	walls,	 this	was	shown	 in	all	our	
amyloidosis patients and is commonly found in literature.14,21,22 
Secondly,	 amyloid	 may	 accumulate	 in	 the	 mucosa	 and	 muscular	
layers	of	the	bowel,	decreasing	motility	by	infiltration	the	smooth	
muscle tissue.23‒25	 Thirdly,	 involvement	 of	 the	 muscular	 layers	
may	result	 in	 loss	of	the	myenteric	 ICC	network,	which	may	 lead	
to dysmotility.26	 A	 study	 into	 transthyretin	 amyloidosis	 patients	
(ie,	a	third	form	of	amyloidosis,	non-AA,	non-AL)	reported	loss	of	
the	ICC	network	in	the	muscularis	propria	of	the	stomach	without	
degeneration	of	the	enteric	nervous	system	(ENS).27	By	our	knowl-
edge,	this	is	the	only	study	into	the	ICC	network	in	amyloidosis	pa-
tients.	Neither	degeneration	nor	loss	of	the	ENS	was	found	in	our	
study,	suggesting	that	loss	of	ICCs	may	precede	damage	of	the	ENS	
in	amyloidosis	patients.	Therefore,	neurodegeneration	and	neuro-
nal	 loss	may	occur	 in	 the	 final	 stage	of	 intestinal	 dysmotility,	 al-
though this might well be a secondary phenomenon. This sequence 
would	explain	intestinal	dysmotility	in	both	AL	and	AA	amyloido-
sis,	but	there	are	obvious	differences	between	the	subtypes.	In	AL	
amyloidosis,	 endoscopic	 findings	 seem	 to	be	 related	 to	muscular	
involvement	 resulting	 in	 constipation	 and	 intestinal	 pseudo-ob-
struction,	while	in	AA	amyloidosis	a	fine	granular	appearance	and	
F I G U R E  4  Hypothesis	about	the	sequential	events	that	cause	intestinal	dysmotility	in	amyloidosis	patients.	The	process	may	start	with	
amyloid	deposition	in	the	blood	vessel	walls,	which	was	found	in	all	AL	and	AA	amyloidosis	patients,	followed	by	mechanical	disruption	
of	the	smooth	muscles,	loss	of	ICC,	and	potential	involvement	of	the	myenteric	plexus	(reflected	in	nerve	fiber	or	neuronal	loss).	Amyloid	
deposits	were	found	in	the	mucosa	of	AA	patients,	which	may	cause	symptoms	of	diarrhea	and	malabsorption,	but	is	not	directly	related	to	
bowel	dysmotility.	“None”	represents	cases	without	amyloid	in	both	mucosa	and	muscularis	propria.	ICC, interstitial cells of Cajal
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friability of the mucosa might be related to diarrhea and malab-
sorption (Table 3).
Our study had several limitations. The study was performed on 
autopsy	material.	Hence,	the	quality	of	the	material	was	not	optimal	
in	 some	cases,	 for	 instance	as	a	 result	of	autolysis	of	 the	mucosal	
layer	or	imperfect	embedding.	Therefore,	only	tissues	with	all	layers	
of the bowel wall present were included. Scoring of clinical dysmo-
tility was difficult due to limited information in the medical dossier 
about symptoms related to intestinal dysmotility. Severe dysmotility 
was	described	in	one	AA	patient	(dysmotility	esophagus,	ileus)	and	
may	 be	 related	 to	 extensive	 amyloid	 deposition,	 ICC	 loss,	 and	 re-
duction	of	nerve	fibers.	Loss	of	nerve	fibers	in	the	myenteric	plexus	
may	have	 contributed	 to	 ileus	 in	 three	other	patients,	 although	 in	
two	of	these,	the	ileus	could	have	been	a	result	from	earlier	bowel	
resections. The available endoscopic information was insufficient to 
conclude anything about the relation between microscopic and mac-
roscopic	changes.	Our	study	was	aimed	on	exploration	of	sequen-
tial events and forms the basis for future research: larger patients 
groups	and	more	tissue	per	patients	are	required.	In	those	studies,	
histological	examination	should	be	combined	with	physiological	and	
endoscopic	 data	 and	 accurate	 knowledge	 of	 clinical	 symptoms	 of	
intestinal	 dysmotility.	 In	 this	way,	 the	 proposed	 sequential	 patho-
genesis of intestinal involvement in amyloidosis can be investigated 
more	precisely.	The	AL	type	of	amyloidosis	could	not	be	confirmed	in	
three	patients	in	the	AL	group,	but	these	patients	were	non-AA	(neg-
ative	amyloid	A	staining)	and	non-hereditary	 transthyretin	amyloi-
dosis (Dutch study population28).	Excluding	these	three	cases	from	
analysis did not affect the results. The degree of amyloid deposition 
in	AA	amyloidosis	may	be	affected	by	treatment	of	the	underlying	
disease	 (in	 all	 but	 one	 patient),	 which	 could	 have	 suppressed	 the	
acute phase response resulting in reduction of the production and 
deposition	of	serum	amyloid	A	protein.
In	conclusion,	the	main	initial	histological	finding	in	patients	with	
amyloidosis was deposition of amyloid in the vasculature. The most 
important sign of muscular damage was the presence of amyloid de-
posits	in	the	musculature,	no	primary	myopathy	or	neuropathy	was	
detected. We hypothesize that the involvement of the intestines 
is	 a	 sequential	 process:	 deposition	 of	 amyloid	 in	 the	 vasculature,	
followed	by	mechanical	 disruption	of	 the	 smooth	muscles,	 loss	 of	
ICC,	 and	potential	 involvement	of	 the	myenteric	plexus.	This	 final	
stage may be accompanied by clinical symptoms of severe intestinal 
dysmotility.
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